This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Lymphocyte-activation gene 3 (LAG3; CD223); PD-1 receptor (PDCD1; PD-1; CD279)	<p>Mouse studies suggest inhibiting both LAG3 and PD-1 could help treat cancer. In two mouse models of cancer, combined injection of anti-Lag3 and anti-Pd-1 antibodies increased the number of tumor-free animals compared with injection of either antibody alone. Next steps could include screening additional cancer types for responsiveness to the combination antibody therapy.</p> <p>At least six companies have antibodies or fusion proteins that target LAG3 or PD-1 in Phase II testing or earlier to treat cancer.</p> <p>SciBX 5(5); doi:10.1038/scibx.2012.120 Published online Feb. 2, 2012</p>	Patents pending; licensing status unavailable	<p>Woo, S.-R. <i>et al. Cancer Res.</i>; published online Dec. 20, 2011; doi:10.1158/0008-5472.CAN-11-1620</p> <p>Contact: Dario A.A. Vignali, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: dario.vignali@stjude.org</p>